The pathogenic contribution of IL-17 producing T-cells (Type 17 T-cells; T17 cells) in psoriasis is substantiated by the high efficacy of psoriasis biologic treatments targeting IL-17 or IL-23 which regulates T17 cells (Figure 1). This evidence concerns the gene IL37 and psoriasis.